Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Akanksha Bakshi

Knight Therapeutics Secures Rights To Rigel's Fostamatinib In Latin America

Knight Therapeutics Inc. (TSX:GUD) (OTC:KHTRF) entered into exclusive license and supply agreements with Rigel Pharmaceuticals (NASDAQ:RIGL), securing the rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.

Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE (fostamatinib disodium hexahydrate) and in Europe under the brand name TAVLESSE for the treatment of chronic immune thrombocytopenia (ITP).

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.